Japan begins TRG-035 tooth trials

A tooth-regrowth drug sounds like sci-fi. But this story is real enough now that it has crossed the line from lab work to human testing. The drug is TRG-035, built by Kyoto University-linked startup Toregem BioPharma, and it is now in Phase 1 trials in Japan for congenital tooth agenesis — people born missing teeth. That last part matters, because the internet version of this story often jumps straight to “adults can regrow lost teeth.” The actual news is narrower, earlier, and more interesting. (toregem.co.jp) ### What is the drug actually trying to do? TRG-035 is an antibody drug that blocks USAG-1, a protein that normally suppresses tooth development. The idea is not to 3D-print a replacement tooth or implant a synthetic one. It is to remove a biological brake and let dormant tooth-forming tissue start developing again. Toregem describes it as a way to activate latent tooth buds and promote eruption of new teeth. (toregem.co.jp)n_Orphan.pdf)) ### Why start with people born missing teeth? Because that is the cleaner first target. Severe congenital hypodontia or oligodontia means six or more permanent teeth never formed in the first place, and current treatment is basically prosthetics — dentures, bridges, implants. Japan’s health ministry gave TRG-035 orphan-drug designation for that indication in September 2025, which usually means the disease is rare, the unmet need is real, and regulators are willing to help move development along. (toregem.co.jp) ### Why does USAG-1 matter so much? USAG-1 has been on researchers’ radar for years because animals missing that signal can develop extra teeth. Older mouse work showed that knocking out USAG-1 led to supernumerary teeth, which gave researchers a very direct clue — this protein is part of the machinery that says “stop” during tooth development. Later work pushed the idea toward therapy by showing that blocking Usag-1 signaling could rescue arrested tooth formation in mouse models. (pubmed.ncbi.nlm.nih.gov) ### So what changed recently? The big change is translational, not conceptual. Toregem says Phase 1 is underway in Japan, and the company has been building the regulatory path around it — AMED backing in 2024, orphan designation in 2025, and a disclosed pre-IND response from the FDA in November 2025 for U.S. development planning. Basically, this is no longer just an academic tooth-development story. It is a drug-development program. (toregem.co.jp)35_Severe_Anodontia_Japan_Orphan.pdf)) ### Did this work in animals? In preclinical work, yes — enough to justify a first-in-human study. Toregem’s own development summary says anti-USAG-1 neutralizing antibodies rescued developmentally arrested tooth germs in animal models, and the company says efficacy was confirmed in animals before moving into Phase 1. That is promising, but promising animal data is not the same thing as a proven human therapy. Plenty of regenerative ideas stumble exactly at that step. (sciencedirect.com) ### Can this help people who lost teeth later in life? Maybe eventually, but that is the leap people keep making too fast. Toregem explicitly says it wants to expand beyond congenital conditions to acquired tooth loss, which is the much bigger market and the version that makes everyone imagine replacing a molar at 60. But the current clinical path is not there yet. The first indication is congenital absence, where dormant developmental pathways may be easier to exploit. (toregem.co.jp) ### What is the catch? Safety first, biology second, hype last. A Phase 1 trial mainly asks whether the drug is tolerable and how it behaves in humans. It does not prove that a missing adult tooth will reappear on schedule. And because USAG-1 interacts with broader developmental signaling pathways, researchers have to be careful that “grow a tooth” does not come with unwanted effects elsewhere. (sciencedirect.com) ### Bottom line? This is a real biotech program, not just a viral post. But the honest version is narrower than the meme: Japan has begun testing a first-in-class tooth-regeneration antibody in humans for a rare congenital condition. That is a big milestone for regenerative dentistry. It is not yet proof that routine tooth regrowth is around the corner.